Sunitinib in patients with cytokine-refiractory metastatic renal cell carcinoma (mRCC)

被引：7
|
作者：
George, D. J. [1 ]
Michaelson, M. D. [2 ]
Rosenberg, J. E. [3 ]
Redman, B. G. [4 ]
Hudes, G. R. [5 ]
Bukowski, R. M. [6 ]
Kim, S. T. [7 ]
Chen, I.
Wilding, G. [8 ]
Motzer, R. J. [9 ]
机构：
[1] Duke Univ, Ctr Med, Durham, NC 27706 USA
[2] Massachusetts Gen Hosp, Boston, MA 02114 USA
[3] Univ Calif San Francisco, San Francisco, CA 94143 USA
[4] Univ Michigan, Ann Arbor, MI 48109 USA
[5] Fox Chase Canc Ctr, Philadelphia, PA USA
[6] Cleveland Clin Taussig Canc Ctr, Cleveland, OH USA
[7] Pfizer Inc, La Jolla, CA USA
[8] Univ Wisconsin, Paul P Carbone Comprehens Canc Ctr, Madison, WI 53706 USA
[9] Mem Sloan Kettering Canc Ctr, Genitourinary Oncol Serv, New York, NY USA
来源：
EJC SUPPLEMENTS | 2007年 / 5卷 / 04期
关键词：
D O I：
10.1016/S1359-6349(07)71148-5
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4517
引用
收藏
页码：304 / 304
页数：1
相关论文
共 50 条
  • [41] A personalized sunitinib (S) first-line approach in elderly patients with metastatic renal cell carcinoma (mRCC).
    Rocca, Maria Cossu
    Iacovelli, Roberto
    Verri, Elena
    Crescio, Claudia
    Aurilio, Gaetano
    Detti, Serena
    Cullura, Daniela
    Nole, Franco
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [42] Sunitinib Rechallenge in Patients With Metastatic Renal Cell Carcinoma
    Nachbargauer, Sebastian
    Bruchbacher, Andreas
    Fajkovic, Harun
    Remzi, Mesut
    Schmidinger, Manuela
    CLINICAL GENITOURINARY CANCER, 2020, 18 (03) : E277 - E283
  • [43] SUNITINIB RECHALLANGE IN METASTATIC RENAL CELL CARCINOMA PATIENTS
    Nagyivanyi, K.
    Biro, K.
    Gyergyay, F.
    Kueronya, Z.
    Nemeth, H.
    Geczi, L.
    ANNALS OF ONCOLOGY, 2012, 23 : 281 - 281
  • [44] Presurgical sunitinib in patients with newly diagnosed metastatic renal cell carcinoma (mRCC): Interim toxicity and feasibility analysis
    Jonasch, E.
    Wood, C. G.
    Pagliaro, L. C.
    Corn, P. G.
    Aparicio, A.
    Marcott, V. D.
    Matin, S. F.
    Tannir, N. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [45] Association of tumor burden characteristics with outcomes in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with sunitinib
    Golshayan, A. R.
    Elson, P.
    Wood, L. S.
    Garcia, J. A.
    Dreicer, R.
    Rini, B. I.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [46] Sunitinib in patients with or without prior nephrectomy (Nx) in an expanded access trial of metastatic renal cell carcinoma (mRCC)
    Szczylik, C.
    Porta, C.
    Bracarda, S.
    Hawkins, R.
    Bjarnason, G. A.
    Oudard, S.
    Lee, S.
    Carteni, G.
    Hariharan, S.
    Gore, M. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [47] A phase II study of intermittent sunitinib in previously untreated patients (pts) with metastatic renal cell carcinoma (mRCC).
    Wood, Laura S.
    Dreicer, Robert
    Garcia, Jorge A.
    Gilligan, Timothy D.
    Ali, Khaled B.
    Haddad, Housam
    Shah, Shetal N.
    Elson, Paul
    Rini, Brian I.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [48] Phase 1/2 study of sunitinib in combination with gefitinib in patients (pts) with metastatic renal cell carcinoma (mRCC)
    Redman, B. G.
    Hudes, G. R.
    Kondagunta, G. V.
    Patel, P. H.
    Kim, S. T.
    Chen, I.
    Motzer, R. J.
    EJC SUPPLEMENTS, 2007, 5 (04): : 302 - 302
  • [49] Sunitinib Rechallenge in Metastatic Renal Cell Carcinoma Patients
    Zama, Ivan N.
    Hutson, Thomas E.
    Elson, Paul
    Cleary, James M.
    Choueiri, Toni K.
    Heng, Daniel Y. C.
    Ramaiya, Nikhil
    Michaelson, M. Dror
    Garcia, Jorge A.
    Knox, Jennifer J.
    Escudier, Bernard
    Rini, Brian I.
    CANCER, 2010, 116 (23) : 5400 - 5406
  • [50] WBC changes as a pharmacodynamic marker of outcome in metastatic renal cell carcinoma (mRCC) patients (Pts) receiving sunitinib
    George, S.
    Richmond, A.
    Elson, P.
    Jin, T.
    Wood, L.
    Garcia, J. A.
    Rini, B. I.
    Finke, J.
    Bukowski, R. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
12345